Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Bacteremia.

Siripen Kanchanasuwan, Jakkapan Rongmuang, Pisud Siripaitoon, Narongdet Kositpantawong, Boonsri Charoenmak, Thanaporn Hortiwakul, Ozioma Forstinus Nwabor, Sarunyou Chusri
Author Information
  1. Siripen Kanchanasuwan: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. ORCID
  2. Jakkapan Rongmuang: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
  3. Pisud Siripaitoon: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
  4. Narongdet Kositpantawong: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
  5. Boonsri Charoenmak: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
  6. Thanaporn Hortiwakul: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
  7. Ozioma Forstinus Nwabor: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. ORCID
  8. Sarunyou Chusri: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. ORCID

Abstract

This study aimed to establish the clinical features, outcomes, and factors associated with mortality in patients with Stenotrophomonas maltophilia (S. maltophilia) septicemia. The characteristics and outcome data used in this retrospective study were collected from medical records at Songklanagarind Hospital. Risk factors for survival were analyzed using χ2-tests, Kaplan−Meier curves, and Cox regression. A total of 117 patients with S. maltophilia bacteremia were analyzed. The patients’ median age was 45 years, 77 (70%) were male, 105 (90%) had comorbidities, 112 (96%) had previously undergone carbapenem therapy, and over half of the patients were on invasive medical devices. Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone showed high susceptibility rates to S. maltophilia, with 93% and 88% susceptibility, respectively. Patients who received appropriate empirical antibiotic treatment had significantly reduced 14-day, 30-day, and in-hospital mortality rates than those who did not (p < 0.001). The days of hospital stay and costs for those who received appropriate and inappropriate empirical antimicrobial treatment were 21 and 34 days (p < 0.001) and 142,463 and 185,663 baht, respectively (p < 0.002). Our results suggest that an appropriate empirical antibiotic(s) is significantly associated with lower 30-day mortality in hospitalized patients with S. maltophilia septicemia.

Keywords

References

  1. J Microbiol Immunol Infect. 2004 Dec;37(6):359-65 [PMID: 15599468]
  2. J Infect Dev Ctries. 2014 Aug 13;8(8):1000-5 [PMID: 25116665]
  3. Biomed Res Int. 2019 Dec 9;2019:4931501 [PMID: 31886220]
  4. PLoS One. 2012;7(5):e37375 [PMID: 22624022]
  5. J Hosp Infect. 2008 Oct;70(2):101-8 [PMID: 18621440]
  6. Clin Infect Dis. 2022 Jul 6;74(12):2089-2114 [PMID: 34864936]
  7. Antimicrob Agents Chemother. 2000 Feb;44(2):287-93 [PMID: 10639352]
  8. J Korean Med Sci. 2013 Jan;28(1):62-6 [PMID: 23341713]
  9. Lancet Infect Dis. 2009 May;9(5):312-23 [PMID: 19393961]
  10. Antimicrob Agents Chemother. 2014;58(1):581-3 [PMID: 24126583]
  11. Medicine (Baltimore). 2002 May;81(3):228-39 [PMID: 11997719]
  12. Int J Hematol. 2013 Mar;97(3):414-20 [PMID: 23430671]
  13. J Antimicrob Chemother. 2000 Jan;45(1):115-7 [PMID: 10629022]
  14. Clin Infect Dis. 2000 Sep;31(3):705-11 [PMID: 11017819]
  15. Clin Infect Dis. 2000 Jan;30(1):195-7 [PMID: 10619754]
  16. J Microbiol Immunol Infect. 2014 Feb;47(1):28-35 [PMID: 23040236]
  17. Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):901-6 [PMID: 18483755]
  18. Clin Microbiol Infect. 2018 Aug;24(8):865-870 [PMID: 29221995]
  19. Antimicrob Agents Chemother. 1997 May;41(5):1140-2 [PMID: 9145884]
  20. J Infect. 2002 Jul;45(1):47-53 [PMID: 12217732]
  21. Medicine (Baltimore). 2016 Aug;95(31):e4375 [PMID: 27495046]
  22. Antimicrob Agents Chemother. 2014;58(1):176-82 [PMID: 24145530]
  23. Future Microbiol. 2009 Nov;4(9):1103-9 [PMID: 19895214]
  24. Scand J Infect Dis. 1994;26(2):163-70 [PMID: 8036472]
  25. Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):13-20 [PMID: 17200840]
  26. Infect Drug Resist. 2020 May 28;13:1559-1566 [PMID: 32547125]
  27. PLoS One. 2021 Jan 6;16(1):e0244673 [PMID: 33406110]

Grants

  1. REC:58368144/Faculty of Medicine, Prince of Songkla University

Word Cloud

Created with Highcharts 10.0.0maltophiliamortalitypatientsSappropriateempiricalp<0studyoutcomesfactorsassociatedStenotrophomonassepticemiacharacteristicsmedicalRiskanalyzedbacteremiasusceptibilityratesrespectivelyPatientsreceivedantibiotictreatmentsignificantly30-day001daysaimedestablishclinicalfeaturesoutcomedatausedretrospectivecollectedrecordsSongklanagarindHospitalsurvivalusingχ2-testsKaplan−MeiercurvesCoxregressiontotal117patients’medianage45years7770%male10590%comorbidities11296%previouslyundergonecarbapenemtherapyhalfinvasivedevicesTrimethoprim-sulfamethoxazoleTMP-SMXfluoroquinoloneshowedhigh93%88%reduced14-dayin-hospitalhospitalstaycostsinappropriateantimicrobial2134142463185663baht002resultssuggestslowerhospitalizedClinicalCharacteristicsOutcomesFactorsMortalityBacteremia

Similar Articles

Cited By